HUE035320T2 - Perfluorocarbon nanoemulsions with endocytosis enhancing surface for gene transfer - Google Patents

Perfluorocarbon nanoemulsions with endocytosis enhancing surface for gene transfer Download PDF

Info

Publication number
HUE035320T2
HUE035320T2 HUE12171341A HUE12171341A HUE035320T2 HU E035320 T2 HUE035320 T2 HU E035320T2 HU E12171341 A HUE12171341 A HU E12171341A HU E12171341 A HUE12171341 A HU E12171341A HU E035320 T2 HUE035320 T2 HU E035320T2
Authority
HU
Hungary
Prior art keywords
nanoemulsion
sirna
component
und
nanocarrier
Prior art date
Application number
HUE12171341A
Other languages
English (en)
Hungarian (hu)
Inventor
Soeren Schreiber
Original Assignee
Soluventis Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soluventis Gmbh filed Critical Soluventis Gmbh
Publication of HUE035320T2 publication Critical patent/HUE035320T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE12171341A 2008-05-19 2009-05-13 Perfluorocarbon nanoemulsions with endocytosis enhancing surface for gene transfer HUE035320T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08156434A EP2123256A1 (en) 2008-05-19 2008-05-19 Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer

Publications (1)

Publication Number Publication Date
HUE035320T2 true HUE035320T2 (en) 2018-05-02

Family

ID=39869983

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12171341A HUE035320T2 (en) 2008-05-19 2009-05-13 Perfluorocarbon nanoemulsions with endocytosis enhancing surface for gene transfer

Country Status (14)

Country Link
US (1) US9616131B2 (enExample)
EP (3) EP2123256A1 (enExample)
JP (1) JP5546534B2 (enExample)
CN (2) CN102847170B (enExample)
AU (1) AU2009249812B2 (enExample)
CA (1) CA2725513C (enExample)
DK (2) DK2510921T3 (enExample)
ES (2) ES2391375T3 (enExample)
HU (1) HUE035320T2 (enExample)
IL (1) IL209205A (enExample)
NZ (1) NZ589417A (enExample)
PL (2) PL2285349T3 (enExample)
WO (1) WO2009141257A1 (enExample)
ZA (1) ZA201008274B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123256A1 (en) 2008-05-19 2009-11-25 Ruhr-Universität Bochum Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
CN103764169B (zh) * 2011-03-31 2017-06-13 康斯坦策·沙费尔 用于非病毒转移核酸的全氟化化合物
CN103251980B (zh) * 2013-05-17 2014-07-02 中国人民解放军第四军医大学 全氟三丁胺与纤维蛋白水凝胶复合的神经导管制备方法
CN103263695B (zh) * 2013-05-17 2014-10-29 中国人民解放军第四军医大学 全氟三乙胺乳液与种子细胞复合的神经导管制备方法
EP2853595A1 (en) * 2013-09-30 2015-04-01 Soluventis GmbH NOTCH 1 specific siRNA molecules
EP3549609A4 (en) * 2016-12-01 2020-07-29 Saitama University ENDOCYTOSIS ACTIVATOR FOR DRUG DELIVERY SYSTEMS
WO2025080939A1 (en) 2023-10-13 2025-04-17 Ultragenyx Pharmaceutical, Inc. Compositions and methods for treating conditions associated with cartilage oligomeric matrix protein (comp) mutations
WO2025128853A2 (en) 2023-12-13 2025-06-19 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating conditions associated with ube3a overexpression

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6050578B2 (ja) 1981-12-25 1985-11-09 日本スチレンペ−パ−株式会社 合成樹脂発泡体の製造法
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
EP0833608A2 (en) * 1995-06-07 1998-04-08 Alliance Pharmaceutical Corporation Reverse fluorocarbon emulsion compositions for drug delivery
US5667809A (en) * 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
JP2001002592A (ja) * 1999-06-18 2001-01-09 Dai Ichi Seiyaku Co Ltd 遺伝子導入用組成物
KR20080046750A (ko) 2000-03-24 2008-05-27 바이오스피어 메디칼 인코포레이티드 능동 색전화용 미소구
US20020155084A1 (en) * 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
KR20030039363A (ko) * 2000-07-20 2003-05-17 오뜨끄리또에 악찌오네르노에 오브셰스뜨보 나우취노-쁘로이즈보드스뜨벤나야 피르마 "뻬르프또란" 의료용 퍼플루오르 유기화합물의 유제 및 그 제조방법 및그것을 이용한 질병 치료 및 예방방법
ATE392812T1 (de) 2001-07-10 2008-05-15 Sonogene Llc Verbesserung der transfektion von dna in die leber
US20040115159A1 (en) 2002-03-29 2004-06-17 Tadlock Charles C Novel nanoemulsions
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
US20070184076A1 (en) 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
EP1844772A1 (en) 2006-04-06 2007-10-17 Polyplus-Transfection SA Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications
EP2123256A1 (en) 2008-05-19 2009-11-25 Ruhr-Universität Bochum Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer

Also Published As

Publication number Publication date
AU2009249812B2 (en) 2013-08-22
CN102112109B (zh) 2016-10-12
CN102847170B (zh) 2016-03-16
EP2510921B1 (en) 2017-07-12
HK1159479A1 (zh) 2012-08-03
DK2285349T3 (da) 2012-10-22
CN102847170A (zh) 2013-01-02
EP2285349A1 (en) 2011-02-23
CA2725513C (en) 2013-07-02
WO2009141257A1 (en) 2009-11-26
US9616131B2 (en) 2017-04-11
PL2285349T3 (pl) 2012-12-31
DK2510921T3 (en) 2017-10-23
CN102112109A (zh) 2011-06-29
AU2009249812A1 (en) 2009-11-26
EP2510921A1 (en) 2012-10-17
NZ589417A (en) 2012-03-30
HK1179533A1 (zh) 2013-10-04
IL209205A (en) 2015-08-31
ES2391375T3 (es) 2012-11-23
CA2725513A1 (en) 2009-11-26
EP2123256A1 (en) 2009-11-25
EP2285349B1 (en) 2012-07-11
IL209205A0 (en) 2011-01-31
ES2642316T3 (es) 2017-11-16
JP2011520936A (ja) 2011-07-21
US20110091561A1 (en) 2011-04-21
JP5546534B2 (ja) 2014-07-09
ZA201008274B (en) 2012-02-29
PL2510921T3 (pl) 2017-12-29

Similar Documents

Publication Publication Date Title
HUE035320T2 (en) Perfluorocarbon nanoemulsions with endocytosis enhancing surface for gene transfer
JP7600208B2 (ja) 拘束された脂質を含むナノ材料およびその使用
Li et al. Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy
CN102170866B (zh) 亲脂性或两亲性治疗剂在纳米乳剂中的包囊
Lu et al. Nanotherapeutics for Alleviating Anesthesia‐Associated Complications
Panghal et al. Nano-based approaches for the treatment of neuro-immunological disorders: A special emphasis on multiple sclerosis
Levina et al. In vivo hypotensive effect of aminosilanol-based nanocomposites bearing antisense oligonucleotides
JPWO2008075706A1 (ja) 間質性肺炎治療剤
Navascuez et al. COSAN-stabilised omega-3 oil-in-water nanoemulsions to prolong lung residence time for poorly water soluble drugs
US20250146021A1 (en) Folding mrna into a nanoscale delivery vehicle
Watabe et al. Bioinspired carbon monoxide delivery using artificial blood attenuates the progression of obliterative bronchiolitis via suppression of macrophage activation by IL-17A
CN117338948A (zh) 一种ace2特异性结合肽修饰的递药系统及其制备方法和应用
HK1159479B (en) Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
HK1179533B (en) Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
US20250367319A1 (en) Targeted Nanomedicine for Treating Fibrotic Lung Disorders
CN119074944B (zh) 经鼻入脑靶向中枢神经的纳米药物递送系统及其制备方法和应用
TW202541786A (zh) 脂質奈米顆粒
Harishkumar et al. Nanosomes for drug delivery
WO2024138370A1 (zh) 一种治疗高尿酸相关疾病的核酸药物及其制备方法和用途
WO2025111297A1 (en) Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
CN120037392A (zh) 一种仿生纳米复合物及其制备方法和在制备治疗动脉粥样硬化病产品中的应用
CN119770672A (zh) 一种心脏靶向的纳米脂质体递送载体、治疗心血管疾病的环状rna药物及其制备方法和应用
JP2021167289A (ja) 水溶性化合物を内包した脂質ナノ粒子
BR102017003860A2 (pt) composição editora de genoma, processo de obtenção e uso da mesma